Does the media favor APGE or BIIB?

In the previous week, Biogen had 30 more articles in the media than Apogee Therapeutics. MarketBeat recorded 41 mentions for Biogen and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Biogen's score of 1.23 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Biogen 31 Very Positive mention(s) 2 Positive mention(s) 6 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media prefer APGE or ALNY?

In the previous week, Alnylam Pharmaceuticals had 19 more articles in the media than Apogee Therapeutics. MarketBeat recorded 30 mentions for Alnylam Pharmaceuticals and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Apogee Therapeutics is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive Alnylam Pharmaceuticals 22 Very Positive mention(s) 1 Positive mention(s) 6 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Does the media refer more to BNTX or APGE?

In the previous week, BioNTech had 8 more articles in the media than Apogee Therapeutics. MarketBeat recorded 19 mentions for BioNTech and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat BioNTech's score of -0.04 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment BioNTech 5 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 4 Negative mention(s) 4 Very Negative mention(s) Neutral Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media refer more to INSM or APGE?

In the previous week, Apogee Therapeutics had 4 more articles in the media than Insmed. MarketBeat recorded 11 mentions for Apogee Therapeutics and 7 mentions for Insmed. Apogee Therapeutics' average media sentiment score of 1.63 beat Insmed's score of 0.90 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 2 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Does the media favor INCY or APGE?

In the previous week, Incyte had 28 more articles in the media than Apogee Therapeutics. MarketBeat recorded 39 mentions for Incyte and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Incyte's score of 1.39 indicating that Apogee Therapeutics is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Incyte 29 Very Positive mention(s) 3 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Apogee Therapeutics 9 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Very Positive

Apogee Therapeutics (APGE) Competitors

$134.97 +0.01 (+0.01%)

As of 08/28/2026 04:00 PM Eastern

Compare

APGE vs. BIIB, ALNY, BNTX, INSM, and INCY

Should you buy Apogee Therapeutics stock or one of its competitors? Apogee Therapeutics's main competitors and comparable companies include Biogen (BIIB), Alnylam Pharmaceuticals (ALNY), BioNTech (BNTX), Insmed (INSM), and Incyte (INCY). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Apogee Therapeutics compare to Biogen?

Apogee Therapeutics (NASDAQ:APGE) and Biogen (NASDAQ:BIIB) are both healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their institutional ownership, profitability, analyst recommendations, media sentiment, earnings, risk, valuation and dividends.

In the previous week, Biogen had 30 more articles in the media than Apogee Therapeutics. MarketBeat recorded 41 mentions for Biogen and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Biogen's score of 1.23 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Biogen	31 Very Positive mention(s)	2 Positive mention(s)	6 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Positive

Biogen has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Biogen, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Biogen	$9.89B	3.26	$1.29B	$5.65	38.67

Biogen has a net margin of 8.32% compared to Apogee Therapeutics' net margin of 0.00%. Biogen's return on equity of 11.18% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Biogen	8.32%	11.18%	6.88%

Apogee Therapeutics has a beta of 0.34, indicating that its share price is 66% less volatile than the broader market. Comparatively, Biogen has a beta of 0.17, indicating that its share price is 83% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 87.9% of Biogen shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by insiders. Comparatively, 0.3% of Biogen shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Apogee Therapeutics presently has a consensus target price of $126.77, suggesting a potential downside of 6.07%. Biogen has a consensus target price of $227.79, suggesting a potential upside of 4.25%. Given Biogen's stronger consensus rating and higher probable upside, analysts plainly believe Biogen is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Biogen	1 Sell rating(s)	13 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.58

Summary

Biogen beats Apogee Therapeutics on 12 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Apogee Therapeutics (NASDAQ:APGE) and Alnylam Pharmaceuticals (NASDAQ:ALNY) are both healthcare companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, valuation, risk, institutional ownership, analyst recommendations, media sentiment, earnings and profitability.

In the previous week, Alnylam Pharmaceuticals had 19 more articles in the media than Apogee Therapeutics. MarketBeat recorded 30 mentions for Alnylam Pharmaceuticals and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Alnylam Pharmaceuticals' score of 1.12 indicating that Apogee Therapeutics is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Alnylam Pharmaceuticals	22 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Alnylam Pharmaceuticals has a net margin of 15.26% compared to Apogee Therapeutics' net margin of 0.00%. Alnylam Pharmaceuticals' return on equity of 84.93% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Apogee Therapeutics	N/A	-29.88%	-28.08%
Alnylam Pharmaceuticals	15.26%	84.93%	14.30%

Apogee Therapeutics currently has a consensus target price of $126.77, indicating a potential downside of 6.07%. Alnylam Pharmaceuticals has a consensus target price of $386.14, indicating a potential upside of 62.86%. Given Alnylam Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Alnylam Pharmaceuticals is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16
Alnylam Pharmaceuticals	0 Sell rating(s)	5 Hold rating(s)	16 Buy rating(s)	3 Strong Buy rating(s)	2.92

Apogee Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market. Comparatively, Alnylam Pharmaceuticals has a beta of 0.3, indicating that its stock price is 70% less volatile than the broader market.

79.0% of Apogee Therapeutics shares are held by institutional investors. Comparatively, 93.0% of Alnylam Pharmaceuticals shares are held by institutional investors. 24.3% of Apogee Therapeutics shares are held by company insiders. Comparatively, 0.9% of Alnylam Pharmaceuticals shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Alnylam Pharmaceuticals has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Alnylam Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A
Alnylam Pharmaceuticals	$3.71B	8.54	$313.75M	$5.38	44.07

Summary

Alnylam Pharmaceuticals beats Apogee Therapeutics on 13 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to BioNTech?

BioNTech (NASDAQ:BNTX) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their risk, institutional ownership, profitability, earnings, dividends, media sentiment, valuation and analyst recommendations.

15.5% of BioNTech shares are owned by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are owned by institutional investors. 19.2% of BioNTech shares are owned by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company is poised for long-term growth.

Apogee Therapeutics has lower revenue, but higher earnings than BioNTech. Apogee Therapeutics is trading at a lower price-to-earnings ratio than BioNTech, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
BioNTech	$2.65B	9.74	-$1.29B	-$7.83	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Apogee Therapeutics has a net margin of 0.00% compared to BioNTech's net margin of -63.54%. BioNTech's return on equity of -6.86% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
BioNTech	-63.54%	-6.86%	-6.00%
Apogee Therapeutics	N/A	-29.88%	-28.08%

BioNTech has a beta of 1.27, indicating that its stock price is 27% more volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

In the previous week, BioNTech had 8 more articles in the media than Apogee Therapeutics. MarketBeat recorded 19 mentions for BioNTech and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat BioNTech's score of -0.04 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
BioNTech	5 Very Positive mention(s)	0 Positive mention(s)	4 Neutral mention(s)	4 Negative mention(s)	4 Very Negative mention(s)	Neutral
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

BioNTech currently has a consensus price target of $127.81, suggesting a potential upside of 25.22%. Apogee Therapeutics has a consensus price target of $126.77, suggesting a potential downside of 6.07%. Given BioNTech's stronger consensus rating and higher probable upside, equities research analysts clearly believe BioNTech is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioNTech	1 Sell rating(s)	4 Hold rating(s)	13 Buy rating(s)	1 Strong Buy rating(s)	2.74
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

Summary

BioNTech beats Apogee Therapeutics on 9 of the 15 factors compared between the two stocks.

How does Apogee Therapeutics compare to Insmed?

Insmed (NASDAQ:INSM) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the better business? We will contrast the two businesses based on the strength of their earnings, profitability, analyst recommendations, valuation, risk, dividends, media sentiment and institutional ownership.

Insmed presently has a consensus price target of $205.52, suggesting a potential upside of 73.38%. Apogee Therapeutics has a consensus price target of $126.77, suggesting a potential downside of 6.07%. Given Insmed's stronger consensus rating and higher possible upside, analysts plainly believe Insmed is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Insmed	1 Sell rating(s)	0 Hold rating(s)	22 Buy rating(s)	2 Strong Buy rating(s)	3.00
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Apogee Therapeutics had 4 more articles in the media than Insmed. MarketBeat recorded 11 mentions for Apogee Therapeutics and 7 mentions for Insmed. Apogee Therapeutics' average media sentiment score of 1.63 beat Insmed's score of 0.90 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Insmed	2 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Insmed has a beta of 0.81, suggesting that its stock price is 19% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, suggesting that its stock price is 66% less volatile than the broader market.

Apogee Therapeutics has a net margin of 0.00% compared to Insmed's net margin of -76.94%. Apogee Therapeutics' return on equity of -29.88% beat Insmed's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Insmed	-76.94%	-123.94%	-44.30%
Apogee Therapeutics	N/A	-29.88%	-28.08%

79.0% of Apogee Therapeutics shares are held by institutional investors. 2.1% of Insmed shares are held by company insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Apogee Therapeutics has lower revenue, but higher earnings than Insmed. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Insmed, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Insmed	$606.42M	42.69	-$1.28B	-$4.11	N/A
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

Summary

Insmed and Apogee Therapeutics tied by winning 8 of the 16 factors compared between the two stocks.

How does Apogee Therapeutics compare to Incyte?

Incyte (NASDAQ:INCY) and Apogee Therapeutics (NASDAQ:APGE) are both healthcare companies, but which is the superior business? We will compare the two businesses based on the strength of their earnings, media sentiment, valuation, profitability, analyst recommendations, institutional ownership, risk and dividends.

Incyte has a net margin of 27.71% compared to Apogee Therapeutics' net margin of 0.00%. Incyte's return on equity of 29.93% beat Apogee Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Incyte	27.71%	29.93%	22.88%
Apogee Therapeutics	N/A	-29.88%	-28.08%

Incyte has higher revenue and earnings than Apogee Therapeutics. Apogee Therapeutics is trading at a lower price-to-earnings ratio than Incyte, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Incyte	$5.82B	4.33	$1.29B	$7.85	15.84
Apogee Therapeutics	N/A	N/A	-$255.84M	-$4.34	N/A

97.0% of Incyte shares are held by institutional investors. Comparatively, 79.0% of Apogee Therapeutics shares are held by institutional investors. 16.2% of Incyte shares are held by insiders. Comparatively, 24.3% of Apogee Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Incyte currently has a consensus price target of $123.10, indicating a potential downside of 1.02%. Apogee Therapeutics has a consensus price target of $126.77, indicating a potential downside of 6.07%. Given Incyte's stronger consensus rating and higher possible upside, analysts clearly believe Incyte is more favorable than Apogee Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Incyte	0 Sell rating(s)	12 Hold rating(s)	12 Buy rating(s)	1 Strong Buy rating(s)	2.56
Apogee Therapeutics	1 Sell rating(s)	15 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.16

In the previous week, Incyte had 28 more articles in the media than Apogee Therapeutics. MarketBeat recorded 39 mentions for Incyte and 11 mentions for Apogee Therapeutics. Apogee Therapeutics' average media sentiment score of 1.63 beat Incyte's score of 1.39 indicating that Apogee Therapeutics is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Incyte	29 Very Positive mention(s)	3 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	1 Very Negative mention(s)	Positive
Apogee Therapeutics	9 Very Positive mention(s)	1 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Incyte has a beta of 0.76, indicating that its stock price is 24% less volatile than the broader market. Comparatively, Apogee Therapeutics has a beta of 0.34, indicating that its stock price is 66% less volatile than the broader market.

Summary

Incyte beats Apogee Therapeutics on 13 of the 15 factors compared between the two stocks.

Get Apogee Therapeutics News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding APGE and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

APGE vs. The Competition

Export

Metric	Apogee Therapeutics	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$8.40B	$3.93B	$7.20B	$12.90B
Dividend Yield	N/A	3.61%	2.54%	11.28%
P/E Ratio	-31.10	11.62	273.16	25.45
Price / Sales	N/A	1,295.89	605.01	76.63
Price / Cash	N/A	106.39	76.74	53.00
Price / Book	7.03	16.53	12.98	6.14
Net Income	-$255.84M	-$22.80M	$3.48B	$348.86M
7 Day Performance	0.16%	-0.31%	0.13%	-0.80%
1 Month Performance	0.50%	9.80%	7.08%	4.13%
1 Year Performance	271.10%	55.66%	24.67%	15.17%

Apogee Therapeutics Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
APGE Apogee Therapeutics	1.6418 of 5 stars	$134.97 +0.0%	$126.77 -6.1%	+271.1%	$8.40B	N/A	N/A	91	News Coverage Positive News
BIIB Biogen	3.6025 of 5 stars	$221.67 +1.6%	$227.07 +2.4%	+65.3%	$32.72B	$9.89B	39.20	7,500	News Coverage Positive News Analyst Forecast
ALNY Alnylam Pharmaceuticals	4.832 of 5 stars	$238.76 +1.2%	$386.62 +61.9%	-46.9%	$31.99B	$3.71B	44.44	2,770	News Coverage Positive News Analyst Forecast Gap Down
BNTX BioNTech	3.2882 of 5 stars	$116.14 +2.9%	$127.81 +10.0%	+2.1%	$29.28B	$3.25B	N/A	7,807	Trending News Options Volume Gap Down
INSM Insmed	3.3784 of 5 stars	$125.86 +1.5%	$205.52 +63.3%	-12.9%	$27.54B	$1.14B	N/A	1,664

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:APGE) was last updated on 8/30/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Apogee Therapeutics (APGE) Competitors

APGE vs. BIIB, ALNY, BNTX, INSM, and INCY

How does Apogee Therapeutics compare to Biogen?

Summary

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Summary

How does Apogee Therapeutics compare to BioNTech?

Summary

How does Apogee Therapeutics compare to Insmed?

Summary

How does Apogee Therapeutics compare to Incyte?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Apogee Therapeutics (APGE) Competitors

APGE vs. BIIB, ALNY, BNTX, INSM, and INCY

How does Apogee Therapeutics compare to Biogen?

Does the media favor APGE or BIIB?

Which has stronger valuation and earnings, APGE or BIIB?

Is APGE or BIIB more profitable?

Which has more volatility and risk, APGE or BIIB?

Do institutionals and insiders have more ownership in APGE or BIIB?

Do analysts prefer APGE or BIIB?

Summary

How does Apogee Therapeutics compare to Alnylam Pharmaceuticals?

Does the media prefer APGE or ALNY?

Is APGE or ALNY more profitable?

Do analysts recommend APGE or ALNY?

Which has more risk & volatility, APGE or ALNY?

Do institutionals and insiders believe in APGE or ALNY?

Which has preferable valuation & earnings, APGE or ALNY?

Summary

How does Apogee Therapeutics compare to BioNTech?

Do institutionals and insiders have more ownership in BNTX or APGE?

Which has better valuation & earnings, BNTX or APGE?

Is BNTX or APGE more profitable?

Which has more volatility & risk, BNTX or APGE?

Does the media refer more to BNTX or APGE?

Do analysts recommend BNTX or APGE?

Summary

How does Apogee Therapeutics compare to Insmed?

Do analysts rate INSM or APGE?

Does the media refer more to INSM or APGE?

Which has more risk & volatility, INSM or APGE?

Is INSM or APGE more profitable?

Do institutionals & insiders hold more shares of INSM or APGE?

Which has stronger valuation & earnings, INSM or APGE?

Summary

How does Apogee Therapeutics compare to Incyte?

Is INCY or APGE more profitable?

Which has stronger earnings & valuation, INCY or APGE?

Do institutionals and insiders believe in INCY or APGE?

Do analysts rate INCY or APGE?

Does the media favor INCY or APGE?

Which has more risk and volatility, INCY or APGE?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

APGE vs. The Competition

Apogee Therapeutics Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools